The purpose of this study is to investigate the effects of using durvalumab plus platinum doublet chemotherapy (carboplatin/abraxane or carboplatin/pemetrexed) with or without abequolixron (RGX-104) in patients with non-small cell lung cancer (NSCLC) before surgery.
Thank you for your interest, but this study will start enrolling soon.
North Carolina (Statewide)
Jared Weiss
Medicine- Oncology
Clinical or Medical
Interventional
Cancer (Lung)
22-2739
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
